Analysis of interleukin-10 promoter single nucleotide polymorphisms and risk of non-Hodgkin lymphoma in a Malaysian population
暂无分享,去创建一个
C. Ng | K. Chang | Yat-Yuen Lim | M. Tai | Somayeh Fani | G. Gan | P. Bee | Y. Chin | T. Ong
[1] N. Rothman,et al. IL10 and TNF variants and risk of non-Hodgkin lymphoma among three Asian populations , 2013, International Journal of Hematology.
[2] P. Zou,et al. Genetic association of interleukin-10 promoter polymorphisms and susceptibility to diffuse large B-cell lymphoma: a meta-analysis. , 2013, Gene.
[3] R. Hassan,et al. Relationship of Epstein-Barr Virus and Interleukin 10 Promoter Polymorphisms with the Risk and Clinical Outcome of Childhood Burkitt Lymphoma , 2012, PloS one.
[4] T. Witzig,et al. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. , 2012, Blood.
[5] R. Gascoyne,et al. MYC and Aggressive B-cell Lymphomas , 2011, Advances in anatomic pathology.
[6] J. Margolick,et al. Cytokine signaling pathway polymorphisms and AIDS-related non-Hodgkin lymphoma risk in the multicenter AIDS cohort study , 2010, AIDS.
[7] Yunbo Sun,et al. Association of interleukin-10 gene polymorphism with cachexia in Chinese patients with gastric cancer. , 2010, Annals of clinical and laboratory science.
[8] Margarida Saraiva,et al. The regulation of IL-10 production by immune cells , 2010, Nature Reviews Immunology.
[9] L. Zeng,et al. Clinical relevance of the interleukin 10 promoter polymorphisms in Chinese Han patients with major trauma: genetic association studies , 2009, Critical care.
[10] L. Castellano,et al. Immunological and Genetic Evidence for a Crucial Role of IL-10 in Cutaneous Lesions in Humans Infected with Leishmania braziliensis1 , 2008, The Journal of Immunology.
[11] M. Shaw,et al. A review of the association between antipsychotic use and hyperprolactinaemia , 2008, Journal of psychopharmacology.
[12] K. Kuliczkowski,et al. Interleukin-10 gene polymorphisms influence the clinical course of non-Hodgkin's lymphoma. , 2008, Tissue antigens.
[13] Manuel A. R. Ferreira,et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.
[14] Yeon-Hee Park,et al. Interleukin‐10 gene polymorphism influences the prognosis of T‐cell non‐Hodgkin lymphomas , 2007, British journal of haematology.
[15] George C. Klein. An Investigation , 2007 .
[16] N. Rothman,et al. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. , 2007, Carcinogenesis.
[17] Peter Boyle,et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. , 2006, Blood.
[18] R. Houot,et al. Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. , 2006, European cytokine network.
[19] F. Marincola,et al. Interleukin‐10 and the immune response against cancer: a counterpoint , 2005, Journal of leukocyte biology.
[20] Weiping Zou,et al. Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.
[21] H. Baz,et al. Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin’s lymphoma , 2004, Journal of Physiology and Biochemistry.
[22] G. Salles,et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. , 2004, Blood.
[23] G. Marti,et al. Studies in NZB IL-10 knockout mice of the requirement of IL-10 for progression of B-cell lymphoma , 2004, Leukemia.
[24] S. O’Brien,et al. Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter -592 C/C genotype. , 2003, Clinical immunology.
[25] P. Costeas,et al. Cytokine polymorphism frequencies in the Greek Cypriot population. , 2003, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.
[26] Randy D Gascoyne,et al. Non-Hodgkin lymphoma , 2016, Medicine.
[27] B. Hancock,et al. Non-Hodgkin lymphoma , 2003, The Lancet.
[28] T. Ottenhoff,et al. Interleukin–10 promoter haplotypes are differently distributed in the Brazilian versus the Dutch population , 2003, Immunogenetics.
[29] Peter Lipsky,et al. Cytokines and their role in lymphoid development, differentiation and homeostasis , 2002, Current opinion in allergy and clinical immunology.
[30] R. Fimmers,et al. Differential regulation of interleukin-10 production by genetic and environmental factors – a twin study , 2002, Genes and Immunity.
[31] M. Hammond,et al. Frequency of cytokine polymorphisms in populations from western Europe, Africa, Asia, the Middle East and South America. , 2002, Human immunology.
[32] D. Harlan,et al. Ethnicity Greatly Influences Cytokine Gene Polymorphism Distribution , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[33] A. Syvänen. Accessing genetic variation: genotyping single nucleotide polymorphisms , 2001, Nature Reviews Genetics.
[34] S. Ye,et al. Note: A MnlI Restriction Site Polymorphism in the Interleukin-10 Gene Promoter , 2001, Biochemical Genetics.
[35] L. Padyukov,et al. Different allelic frequencies of several cytokine genes in Hong Kong Chinese and Swedish Caucasians , 2001, Genes and Immunity.
[36] R. Westendorp,et al. Novel Single Nucleotide Polymorphisms in the Distal IL-10 Promoter Affect IL-10 Production and Enhance the Risk of Systemic Lupus Erythematosus1 , 2001, The Journal of Immunology.
[37] B. Bonavida,et al. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[38] K. Weiss,et al. How many diseases does it take to map a gene with SNPs? , 2000, Nature Genetics.
[39] H. Granger,et al. Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10. , 2000, Blood.
[40] T. Huizinga,et al. Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus , 1999, Genes and Immunity.
[41] L. Klareskog,et al. Increased number of interleukin-10-producing cells in systemic lupus erythematosus patients and their first-degree relatives and spouses in Icelandic multicase families. , 1999, Arthritis and rheumatism.
[42] P. Woo,et al. Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. , 1999, Arthritis and rheumatism.
[43] M. Caligiuri,et al. A review of the association between interleukin-10 and human B-cell malignancies , 1998, Cancer Immunology, Immunotherapy.
[44] J. Lanchbury,et al. Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. , 1998, Arthritis and rheumatism.
[45] M. Feldmann,et al. Interleukin‐10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl‐2 , 1997, Immunology.
[46] M. Lazarus,et al. An investigation of polymorphism in the interleukin-10 gene promoter. , 1997, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.
[47] D. Boomsma,et al. Genetic influence on cytokine production and fatal meningococcal disease , 1997, The Lancet.
[48] J. Blay,et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. , 1996, Cancer research.
[49] P. Galieni,et al. Prognostic value of serum IL‐10 and soluble IL‐2 receptor levels in aggressive non‐Hodgkin's lymphoma , 1994, British journal of haematology.
[50] J. Blay,et al. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. , 1993, Blood.
[51] J. Banchereau,et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[52] T. Mosmann,et al. IL-10, a novel growth cofactor for mature and immature T cells. , 1990, Journal of immunology.
[53] T. Mosmann,et al. Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells , 1990, The Journal of experimental medicine.
[54] Gerome Breen,et al. Genetic Variation , 2020, Population Genetics with R.
[55] J. Touraine,et al. Immunosuppressive networks in the tumour environment and their effect in dendritic cells. , 2009, Biochimica et biophysica acta.
[56] 稲垣 淳. Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma : high interleukin-5 and -10 levels are significant unfavorable prognostic factors , 2007 .
[57] Theodore R Holford,et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. , 2006, The Lancet. Oncology.
[58] M. Rose-Zerilli,et al. Interleukin-10 Polymorphisms, Cancer Susceptibility and Prognosis , 2005, Familial Cancer.
[59] R. Mertelsmann,et al. Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology , 2004, Annals of Hematology.
[60] Y. Lévy,et al. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. , 1994, The Journal of clinical investigation.
[61] Christopher L. Claggett. The investigation. , 1978, Hospital supervisor's bulletin.